Hanmi Science stock holds KRW 50,500 as earnings forecasts improve

Published on 09/23/2026 at 00:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hanmi Science stock closed at KRW 50,500 on September 22, 2026, down 0.59 percent. iM Securities sees 2026 revenue rising 9.0 percent.

Hanmi Science, KR7008930000, Illustration mit AI erstellt.

Hanmi Science Co., Ltd. (KR7008930000) closed at KRW 50,500 on the KOSPI on September 22, 2026, down KRW 300, or 0.59 percent, from the previous close. The share price sets the market backdrop for a new earnings forecast centered on faster profitability improvement.

Forecast points to higher profit

According to Daum on September 22, 2026, iM Securities estimates 2026 revenue at KRW 1.4791 trillion, an increase of 9.0 percent from the previous year. The same forecast puts operating profit at KRW 178.3 billion, up 28.6 percent year over year.

The forecast implies that operating profit is expected to grow more than three times as fast as revenue in percentage terms. That comparison makes margin improvement the central financial issue in the current valuation discussion.

Drug control role supports outlook

Daum reported on September 22, 2026, that iM Securities analyst Lee Sang-heon sees Hanmi Science's position as a drug development control center supporting higher patent allocation and business contribution revenue. The report did not provide a formal rating or price target.

The same estimate places controlling-interest net income at KRW 174.3 billion in 2026, a 47.2 percent increase from the prior year. Net income growth above both revenue and operating profit growth would further increase the importance of execution against the forecast.

Stock stays near KRW 50,000

Hanmi Science stock traded at KRW 50,200 during the September 22, 2026 session, 1.18 percent below the previous close before ending at KRW 50,500. The two market levels show a narrow intraday range around KRW 50,000 while the earnings outlook points to a wider gap between sales growth and profit growth.

For investors, the measurable checkpoint is whether the projected 28.6 percent operating profit increase is reflected in the next reported period. The forecast is an estimate rather than a reported result, so the distinction between expected and delivered earnings remains material.

Market data and company details

The September 22, 2026 closing price was KRW 50,500 on the KOSPI. Hanmi Science is identified by ticker 008930 and operates in the pharmaceutical and healthcare sector.